PMC:7305592 / 5729-7262 JSONTXT

{"target":"http://pubannotation.org/docs/sourcedb/PMC/sourceid/7305592","sourcedb":"PMC","sourceid":"7305592","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7305592","text":"The present study is an explorative sub-study of a larger prospective study on achievement of the goals metastatic lung cancer patients and their oncologists have when starting a palliative systemic treatment as part of usual care (chemotherapy, immunotherapy or targeted therapy with tyrosine kinase inhibitors (TKIs)) (Mieras et al.: What goals do patients and oncologists have when starting a medical treatment for metastatic lung cancer?, submitted). During the patients’ informed consent procedure in the previous study, patients and relatives were asked to choose a relative to participate in the present study if the patient is deceased. Inclusion criteria were ability to give informed consent, possessing a telephone and willing to participate. During the structured telephone interview with relatives of deceased metastatic lung cancer patients we asked to what extent they felt that the goals patients had when starting a systemic treatment were achieved. The telephone interview was conducted with relatives a minimum of 6 weeks after the patient had died, which we feel is an appropriate time frame to be able to recall the treatment, but it not too early after a loved one has passed. To enhance the rigor in the study, the researcher who interviewed the relatives was transparent, i.e. not the treating physician of the patient. Additionally, the interviews were all conducted in the same way, following the same order in the questionnaire and performed by one researcher (AM, between February 2017 and November 2019).","tracks":[]}